Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564504 | 0.98 | GHSR (0.56) | GHSRIL23RKISS1RUTS2RPRMT1 | |
| SCHEMBL29564832 | 0.98 | GHSR (0.56) | GHSRIL23RKISS1RUTS2RPRMT1 | |
| SCHEMBL11420715 | 0.97 | IL23R (0.59) | GHSRIL23RKISS1RUTS2RPRMT1 | |
| SCHEMBL11420763 | 0.97 | IL23R (0.59) | GHSRIL23RKISS1RUTS2RPRMT1 | |
| SCHEMBL29522651 | 0.96 | GHSR (0.60) | GHSRIL23RKISS1RUTS2R | |
| SCHEMBL31514545 | 0.96 | GHSR (0.59) | GHSRIL23RKISS1RUTS2R | |
| SCHEMBL30602952 | 0.96 | GHSR (0.59) | GHSRIL23RKISS1RUTS2R | |
| SCHEMBL30979729 | 0.95 | GHSR (0.60) | GHSRIL23RKISS1RUTS2R | |
| SCHEMBL30276259 | 0.95 | GHSR (0.60) | GHSRIL23RKISS1RUTS2R | |
| SCHEMBL29938488 | 0.95 | GHSR (0.59) | GHSRIL23RKISS1RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | disclosed |
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885KISS1R 1146/4885 |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | GHSR, GIPR, GHRHR | GHSR 1/4885IL23R 158/4885KISS1R 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.